Lexeo Therapeutics (LXEO) Cash from Operations (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Cash from Operations data on file, last reported at 21144000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 2.63% year-over-year to 21144000.0; the trailing twelve-month figure through Mar 2026 stood at 97989000.0 (down 11.35% YoY), and the FY2025 full-year result was 98561000.0, down 21.45% from the prior year.
• Cash from Operations eased to 21144000.0 in Q1 2026, from 20079000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 13192000.0 in Q2 2023 to a low of 29547000.0 in Q3 2025.
• A 5-year average of 19784142.86 and a median of 19226500.0 in 2023 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations tumbled 102.6% in 2024 and increased 29.11% in 2025, its largest moves.
• Tracing LXEO's Cash from Operations over 5 years: stood at 16626000.0 in 2022, then gained by 15.91% to 13981000.0 in 2023, then tumbled by 102.6% to 28326000.0 in 2024, then advanced by 29.11% to 20079000.0 in 2025, then slipped by 5.3% to 21144000.0 in 2026.
• Business Quant data shows LXEO's Cash from Operations at 21144000.0 in Q1 2026, 20079000.0 in Q4 2025, and 29547000.0 in Q3 2025.